-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $8

Benzinga·09/12/2025 10:35:28
Listen to the news
HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $7 to $8.